Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free TRIB Stock Alerts

Trinity Biotech (TRIB) Competitors

Trinity Biotech logo
$0.61 -0.01 (-1.62%)
Closing price 03:59 PM Eastern
Extended Trading
$0.61 0.00 (-0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TRIB vs. CALC, MTEX, LIMN, ADXN, and NCNA

Should you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include CalciMedica (CALC), Mannatech (MTEX), Liminatus Pharma (LIMN), Addex Therapeutics (ADXN), and NuCana (NCNA). These companies are all part of the "pharmaceutical products" industry.

How does Trinity Biotech compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

CalciMedica has higher earnings, but lower revenue than Trinity Biotech. CalciMedica is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CalciMedicaN/AN/A-$29.56M-$1.97N/A
Trinity Biotech$43.78M0.05-$37.38M-$9.40N/A

In the previous week, Trinity Biotech had 2 more articles in the media than CalciMedica. MarketBeat recorded 3 mentions for Trinity Biotech and 1 mentions for CalciMedica. Trinity Biotech's average media sentiment score of 0.67 beat CalciMedica's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CalciMedica
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Trinity Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

79.0% of Trinity Biotech shares are owned by institutional investors. 41.5% of CalciMedica shares are owned by company insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CalciMedica has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat CalciMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
CalciMedicaN/A -1,093.51% -151.17%
Trinity Biotech -85.36%N/A -36.62%

CalciMedica currently has a consensus target price of $13.00, indicating a potential upside of 2,061.26%. Given CalciMedica's stronger consensus rating and higher probable upside, equities analysts plainly believe CalciMedica is more favorable than Trinity Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CalciMedica
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

CalciMedica and Trinity Biotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Trinity Biotech compare to Mannatech?

Mannatech (NASDAQ:MTEX) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Mannatech has a net margin of -14.08% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Mannatech-14.08% -398.35% -45.63%
Trinity Biotech -85.36%N/A -36.62%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Mannatech has higher revenue and earnings than Trinity Biotech. Mannatech is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$108.04M0.09-$15.21M-$8.00N/A
Trinity Biotech$43.78M0.05-$37.38M-$9.40N/A

In the previous week, Trinity Biotech had 2 more articles in the media than Mannatech. MarketBeat recorded 3 mentions for Trinity Biotech and 1 mentions for Mannatech. Trinity Biotech's average media sentiment score of 0.67 beat Mannatech's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mannatech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Trinity Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Trinity Biotech beats Mannatech on 7 of the 13 factors compared between the two stocks.

How does Trinity Biotech compare to Liminatus Pharma?

Trinity Biotech (NASDAQ:TRIB) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Liminatus Pharma has lower revenue, but higher earnings than Trinity Biotech. Liminatus Pharma is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trinity Biotech$43.78M0.05-$37.38M-$9.40N/A
Liminatus PharmaN/AN/A-$10.21M-$0.15N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Liminatus Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Trinity Biotech had 3 more articles in the media than Liminatus Pharma. MarketBeat recorded 3 mentions for Trinity Biotech and 0 mentions for Liminatus Pharma. Trinity Biotech's average media sentiment score of 0.67 beat Liminatus Pharma's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Trinity Biotech Positive
Liminatus Pharma Neutral

79.0% of Trinity Biotech shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Liminatus Pharma has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%.

Company Net Margins Return on Equity Return on Assets
Trinity Biotech-85.36% N/A -36.62%
Liminatus Pharma N/A N/A -402.52%

Summary

Trinity Biotech beats Liminatus Pharma on 8 of the 11 factors compared between the two stocks.

How does Trinity Biotech compare to Addex Therapeutics?

Trinity Biotech (NASDAQ:TRIB) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Addex Therapeutics had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 4 mentions for Addex Therapeutics and 3 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 0.67 beat Addex Therapeutics' score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Trinity Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Addex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Addex Therapeutics has lower revenue, but higher earnings than Trinity Biotech. Addex Therapeutics is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trinity Biotech$43.78M0.05-$37.38M-$9.40N/A
Addex Therapeutics$31.23K278.41$8.02M-$5.74N/A

Addex Therapeutics has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Trinity Biotech-85.36% N/A -36.62%
Addex Therapeutics N/A -80.69%-69.69%

Summary

Trinity Biotech beats Addex Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Trinity Biotech compare to NuCana?

NuCana (NASDAQ:NCNA) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

NuCana has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat NuCana's return on equity.

Company Net Margins Return on Equity Return on Assets
NuCanaN/A -189.94% -130.93%
Trinity Biotech -85.36%N/A -36.62%

In the previous week, Trinity Biotech had 3 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Trinity Biotech and 0 mentions for NuCana. Trinity Biotech's average media sentiment score of 0.67 beat NuCana's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
NuCana Neutral
Trinity Biotech Positive

44.0% of NuCana shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuCana
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Trinity Biotech has higher revenue and earnings than NuCana. Trinity Biotech is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuCanaN/AN/A-$38.71M-$127.73N/A
Trinity Biotech$43.78M0.05-$37.38M-$9.40N/A

Summary

Trinity Biotech beats NuCana on 9 of the 12 factors compared between the two stocks.

Get Trinity Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRIB vs. The Competition

Export
MetricTrinity BiotechMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$2.19M$8.15B$6.25B$11.87B
Dividend YieldN/A2.45%2.73%5.21%
P/E Ratio-0.06119.4629.0328.47
Price / Sales0.057.43476.1060.92
Price / CashN/A17.3227.6236.52
Price / Book-0.033.539.676.67
Net Income-$37.38M$223.69M$3.55B$332.53M
7 Day Performance-0.60%0.07%1.75%2.03%
1 Month Performance1.00%10.16%5.66%9.23%
1 Year Performance-84.96%0.93%34.42%39.62%

Trinity Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRIB
Trinity Biotech
0.3528 of 5 stars		$0.61
-1.6%		N/AN/A$2.19M$43.78MN/A480
CALC
CalciMedica
1.4184 of 5 stars		$0.59
+1.0%		$13.00
+2,103.0%		N/A$9.20MN/AN/A30
MTEX
Mannatech
0.1247 of 5 stars		$4.68
-1.7%		N/AN/A$9.19M$108.04MN/A250
LIMN
Liminatus Pharma
0.2888 of 5 stars		$0.20
+2.2%		N/AN/A$8.90MN/AN/AN/A
ADXN
Addex Therapeutics
0.2941 of 5 stars		$6.59
-5.9%		N/AN/A$8.62M$460KN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TRIB) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel